Increasing Varenicline Dose in Smokers Who Do Not Respond to the Standard Dosage: A Randomized Clinical Trial | Clinical Pharmacy and Pharmacology | JAMA Internal Medicine | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
West  R, Baker  CL, Cappelleri  JC, Bushmakin  AG.  Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt.  Psychopharmacology (Berl). 2008;197(3):371-377.PubMedGoogle ScholarCrossref
Gonzales  D, Rennard  SI, Nides  M,  et al; Varenicline Phase 3 Study Group.  Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation.  JAMA. 2006;296(1):47-55.PubMedGoogle ScholarCrossref
Jorenby  DE, Hays  JT, Rigotti  NA,  et al; Varenicline Phase 3 Study Group.  Efficacy of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation.  JAMA. 2006;296(1):56-63.PubMedGoogle ScholarCrossref
Aubin  HJ, Bobak  A, Britton  JR,  et al.  Varenicline versus transdermal nicotine patch for smoking cessation.  Thorax. 2008;63(8):717-724.PubMedGoogle ScholarCrossref
Hajek  P, McRobbie  HJ, Myers  KE, Stapleton  J, Dhanji  AR.  Use of varenicline for 4 weeks before quitting smoking: decrease in ad lib smoking and increase in smoking cessation rates.  Arch Intern Med. 2011;171(8):770-777.PubMedGoogle ScholarCrossref
Faessel  HM, Smith  BJ, Gibbs  MA, Gobey  JS, Clark  DJ, Burstein  AH.  Single-dose pharmacokinetics of varenicline, a selective nicotinic receptor partial agonist, in healthy smokers and nonsmokers.  J Clin Pharmacol. 2006;46(9):991-998.PubMedGoogle ScholarCrossref
Faessel  HM, Gibbs  MA, Clark  DJ, Rohrbacher  K, Stolar  M, Burstein  AH.  Multiple-dose pharmacokinetics of the selective nicotinic receptor partial agonist, varenicline, in healthy smokers.  J Clin Pharmacol. 2006;46(12):1439-1448.PubMedGoogle ScholarCrossref
Rollema  H, Faessel  HM, Williams  KE.  Varenicline overdose in a teenager.  Clin Toxicol (Phila). 2009;47(6):605.PubMedGoogle ScholarCrossref
Jiménez-Ruiz  CA, Barrios  M, Peña  S,  et al.  Increasing the dose of varenicline in patients who do not respond to the standard dose.  Mayo Clin Proc. 2013;88(12):1443-1445.PubMedGoogle ScholarCrossref
Hedlund  AJ, Broderick  M, Shah  N, Cantrell  L.  Varenicline overdose in a teenager.  Clin Toxicol (Phila). 2009;47(4):371.PubMedGoogle ScholarCrossref
McEwan  A, Hajek  P, McRobbie  H, West  R.  Manual of Smoking Cessation: A Guide for Counsellors and Practitioners. Oxford, England: Wiley-Blackwell; 2006.
Heatherton  TF, Kozlowski  LT, Frecker  RC, Fagerström  KO.  The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire.  Br J Addict. 1991;86(9):1119-1127.PubMedGoogle ScholarCrossref
West  R, Hajek  P.  Evaluation of the Mood and Physical Symptoms Scale (MPSS) to assess cigarette withdrawal.  Psychopharmacology (Berl). 2004;177(1-2):195-199.PubMedGoogle ScholarCrossref
West  R, Hajek  P, Burrows  S.  Effect of glucose tablets on craving for cigarettes.  Psychopharmacology (Berl). 1990;101(4):555-559.PubMedGoogle ScholarCrossref
McRobbie  H, Hajek  P.  Effects of rapid smoking on post-cessation urges to smoke.  Addiction. 2007;102(3):483-489.PubMedGoogle ScholarCrossref
West  R, Hajek  P, Stead  L, Stapleton  J.  Outcome criteria in smoking cessation trials.  Addiction. 2005;100(3):299-303.PubMedGoogle ScholarCrossref
Niaura  R, Hays  JT, Jorenby  DE,  et al.  The efficacy and safety of varenicline for smoking cessation using a flexible dosing strategy in adult smokers.  Curr Med Res Opin. 2008;24(7):1931-1941.PubMedGoogle ScholarCrossref
Original Investigation
February 2015

Increasing Varenicline Dose in Smokers Who Do Not Respond to the Standard Dosage: A Randomized Clinical Trial

Author Affiliations
  • 1United Kingdom Centre for Tobacco and Alcohol Studies, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, England
JAMA Intern Med. 2015;175(2):266-271. doi:10.1001/jamainternmed.2014.6916

Importance  Standard varenicline tartrate dosing was formulated to avoid adverse effects (primarily nausea), but some patients may be underdosed. To our knowledge, no evidence-based guidance exists for physicians considering increasing varenicline dose if there is no response to the standard dosage.

Objective  To determine whether increasing varenicline dose in patients showing no response to the standard dosage improves treatment efficacy.

Design, Setting, and Participants  In a double-blind randomized placebo-controlled trial, 503 smokers attending a stop smoking clinic commenced varenicline use 3 weeks before their target quit date (TQD). Two hundred participants reporting no strong nausea, no clear reduction in smoking enjoyment, and less than 50% reduction in their baseline smoking on day 12 received additional tablets of varenicline or placebo.

Interventions  All participants began standard varenicline tartrate dosing, gradually increasing to 2 mg/d. Dose increases of twice-daily varenicline (0.5 mg) or placebo took place on days 12, 15, and 18 (up to a maximum of 5 mg/d).

Main Outcomes and Measures  Participants rated their smoking enjoyment during the prequit period and withdrawal symptoms weekly for the first 4 weeks after the TQD. Continuous validated abstinence rates were assessed at 1, 4, and 12 weeks after the TQD.

Results  The dose increase reduced smoking enjoyment during the prequit period, with mean (SD) ratings of 1.7 (0.8) for varenicline vs 2.1 (0.7) for placebo (P = .001). It had no effect on the mean (SD) frequency of urges to smoke at 1 week after the TQD, their strength, or the severity of withdrawal symptoms: these ratings for varenicline vs placebo were 2.7 (1.1) vs 2.6 (0.9) (P = .90), 2.6 (1.1) vs 2.8 (1.0) (P = .36), and 1.5 (0.4) vs 1.6 (0.5) (P = .30), respectively. The dose increase also had no effect on smoking cessation rates for varenicline vs placebo at 1 week (37 [37.0%] vs 48 [48.0%], P = .14), 4 weeks (51 [51.0%] vs 59 [59.0%], P = .32), and 12 weeks (26 [26.0%] vs 23 [23.0%], P = .61) after the TQD. There was significantly more nausea (P < .001) and vomiting (P < .001) reported in the varenicline arm than in the placebo arm.

Conclusions and Relevance  Increasing varenicline dose in smokers with low response to the drug had no significant effect on tobacco withdrawal symptoms or smoking cessation. Physicians often consider increasing the medication dose if there is no response to the standard dosage. This approach may not work with varenicline.

Trial Registration Identifier: NCT01206010